Bolniki so bili randomizirani v skupino, ki je prejemala zdravilo Tarceva in v skupino, ki je prejemala placebo enkrat na dan neprekinjeno ter gemcitabin intravensko (1000 mg/ m2, cikel 1: na 1., 8., 15., 22., 29., 36. in 43. dan 8- tedenskega cikla; cikel 2 in nadaljnji cikli: 1., 8. in 15. dan 4- tedenskega cikla [ odobreni odmerek in shema za rak trebušne slinavke, glejte Povzetek glavnih značilnosti zdravila za gemcitabin ]).
Patients were randomised to receive Tarceva or placebo once daily on a continuous schedule plus gemcitabine IV (1000 mg/m2, Cycle 1 - Days 1, 8, 15, 22, 29, 36 and 43 of an 8 week cycle; Cycle 2 and subsequent cycles - Days 1, 8 and 15 of a 4 week cycle [approved dose and schedule for pancreatic cancer, see the gemcitabine SPC]).